Mirum Pharmaceuticals, Inc.
MIRMNext catalyst
Volixibat
Primary Biliary Cholangitis
Get an email about MIRM's next catalysts
Track Mirum Pharmaceuticals (MIRM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 5 more upcoming events in our data (earnings, Phase 3 readout, Phase 2 readout).See the timeline
6 upcoming, 1 past
MIRM Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.53 | FQ end Sep/2026 | Call: tbd
Volixibat Phase 2 Est. Readout (VANTAGE)
Primary completion for Volixibat trial (NCT05050136) in Primary Biliary Cholangitis
SourceBrelovitug Phase 3 Est. Readout
Estimated primary completion for Brelovitug trial (NCT07200908) in Chronic Hepatitis D Infection. Topline data typically follows completion by weeks to months.
SourceBulevirtide and Brelovitug Phase 3 Est. Readout
Primary completion for Bulevirtide and Brelovitug trial (NCT07200908) in Chronic Hepatitis D Infection
SourceBrelovitug (BJT-778) Phase 3 Est. Readout
Primary completion for Brelovitug (BJT-778) trial (NCT07454837) in Chronic Hepatitis D
SourceMRM-3379 Phase 2 Est. Readout
Primary completion for MRM-3379 trial (NCT07209462) in Fragile X Syndrome
SourceHow MIRM's past catalysts played out
Market Overview
Stock performance and key metrics
Open-Label CDCA
CTX
Maralixibat
Biliary Atresia
Blinded CDCA
CTX
Brelovitug
Chronic Hepatitis D Infection
Bulevirtide and Brelovitug
Chronic Hepatitis D Infection
Brelovitug (BJT-778)
Chronic Hepatitis D
Delayed Treatment with Brelovitug
Chronic Hepatitis D Infection
Rescue Medication CDCA
CTX
CDCA Weight-Based Dose TID
CTX
Cholic acid
Inborn Errors of Bile Acid Synthesis
Cholic Acids
Infantile Refsum's Disease
LUM001 (Maralixibat)
Alagille Syndrome
MRM-3379 Open-Label
Fragile X Syndrome
Volixibat
Primary Biliary Cholangitis
Ursodeoxycholic Acid
PBC
MRM-3379
Fragile X Syndrome
LUM001
Alagille Syndrome
Middle Dose of MRM-3379
Fragile X Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open-Label CDCA | Phase 3 | CTX | - | - |
Maralixibat | Phase 3 | Biliary Atresia | - | - |
Blinded CDCA | Phase 3 | CTX | - | - |
Brelovitug | Phase 3 | Chronic Hepatitis D Infection | - | - |
Bulevirtide and Brelovitug | Phase 3 | Chronic Hepatitis D Infection | - | - |
Brelovitug (BJT-778) | Phase 3 | Chronic Hepatitis D | - | - |
Delayed Treatment with Brelovitug | Phase 3 | Chronic Hepatitis D Infection | - | - |
Rescue Medication CDCA | Phase 3 | CTX | - | - |
CDCA Weight-Based Dose TID | Phase 3 | CTX | - | - |
Cholic acid | Phase 3 | Inborn Errors of Bile Acid Synthesis | - | - |
Cholic Acids | Phase 3 | Infantile Refsum's Disease | - | - |
LUM001 (Maralixibat) | Phase 2 | Alagille Syndrome | - | - |
MRM-3379 Open-Label | Phase 2 | Fragile X Syndrome | - | - |
Volixibat | Phase 2 | Primary Biliary Cholangitis | - | - |
Ursodeoxycholic Acid | Phase 2 | PBC | - | - |
MRM-3379 | Phase 2 | Fragile X Syndrome | - | - |
LUM001 | Phase 2 | Alagille Syndrome | - | - |
Middle Dose of MRM-3379 | Phase 2 | Fragile X Syndrome | - | - |
Alagille Syndrome
3 drugs in this indication
Fragile X Syndrome
2 drugs in this indication
CTX
2 drugs in this indication
Inborn Errors of Bile Acid Synthesis
1 drug in this indication
PBC
1 drug in this indication
Biliary Atresia
1 drug in this indication
Primary Biliary Cholangitis
1 drug in this indication
Infantile Refsum's Disease
1 drug in this indication
Hepatitis Delta
1 drug in this indication
ultra-rare soft tissue disease (genetic disease that turns muscle and connective tissue to bone)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Mirum Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in Mirum Pharmaceuticals, Inc.'s (MIRM) pipeline across Phase 3, Phase 2. Its lead program is Brelovitug (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mirum Pharmaceuticals, Inc.'s next FDA catalyst?→
Mirum Pharmaceuticals, Inc.'s (MIRM) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MIRM biotech catalysts?→
Add MIRM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mirum Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.